Fenretinide: A Potential Treatment for Endometriosis

Area of Science:

• Reproductive biology
• Molecular medicine
• Oncology

Background:

• Endometriosis is characterized by decreased retinoic acid (RA) production, leading to reduced estrogen metabolism and resistance to apoptosis.
• Synthetic retinoid analogues like fenretinide promote apoptosis with lower toxicity compared to other retinoids.

Purpose of the Study:

• To investigate the potential of fenretinide to induce apoptosis in endometriotic cells and tissues.
• To evaluate fenretinide's effect on the retinoic acid (RA) signaling pathway in endometriosis.
• To assess fenretinide's efficacy in reducing endometriosis disease burden in vivo.

Main Methods:

• Primary endometriotic stromal cells were treated with varying doses of fenretinide.
• Cell count, viability, apoptosis markers (PARP), and proliferation markers (PCNA) were assessed.
• Gene expression of RA signaling components (STRA6, CRABP2, FABP5) was analyzed via qRT-PCR.
• Fenretinide's effect on endometriotic lesion volume was evaluated in a mouse xenograft model.

Main Results:

• Fenretinide significantly decreased endometriotic cell count and viability in a dose-dependent manner.
• Treatment increased apoptosis marker PARP and decreased proliferation marker PCNA.
• Fenretinide induced STRA6 expression, a gene involved in retinoid uptake, while CRABP2 and FABP5 remained unchanged.
• In vivo, fenretinide treatment significantly reduced endometriotic lesion xenograft volume.

Conclusions:

• Fenretinide induces apoptosis in endometriotic cells and reduces lesion size, potentially by increasing STRA6 expression and restoring retinoid availability.
• Targeting the RA signaling pathway with fenretinide represents a promising novel therapeutic strategy for endometriosis.
• Fenretinide demonstrates efficacy in both in vitro and in vivo models of endometriosis.